Current Management of Primary Cutaneous CD30+ T-cell Lymphoproliferative Disorders
November 30th 2009The purpose of this review is to familiarize oncologists with the clinical and pathologic features of this relatively rare disease spectrum. This should enable appropriate clinical management and reassurance of patients concerned about their prognosis.